Monitoring and surveillance of chronic non-communicable diseases: progress and capacity in high-burden countries.
Ala Alwan, David R Maclean, Leanne M Riley...
https://pubmed.ncbi.nlm.nih.gov/21074258Actively Recruiting
Age: 21Years - 60Years
All Genders
ID06698341
Understanding Novel Gene Variants in Acute Myocardial Infarction in Young Adults
Led by National Heart Centre Singapore · Updated on 2024-11-21
1200
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cardiovascular disease (CVD) causes significant illness and death worldwide, yet many unknowns remain about its development. This study focuses on young adults who have experienced acute myocardial infarction (AMI), particularly those under 50 with few traditional cardiovascular risk factors, and those aged 51-60 with no more than two risk factors excluding diabetes. Researchers aim to identify new gene variants and biomarkers linked to early heart attacks in Chinese, Malay, and Indian patients to better understand and potentially prevent CVD in these groups. Participants in this observational study will be grouped by age and cardiovascular risk factor status. Group 1 includes patients 50 years old or younger regardless of risk factors, while Group 2 includes patients aged 51-60 with no more than two risk factors excluding diabetes. The main procedure involves blood draws to collect samples for genomic, proteomic, and metabolomic analyses to discover novel genes and proteins associated with myocardial infarction. During the study, participants will provide informed consent and comply with study visits and procedures, including blood collection. Researchers will analyze the samples to identify new gene variants and other biomarkers linked to early heart attacks over a five-year period. The primary outcome is to find gene variants associated with MI onset, while secondary outcomes include identifying proteins, lipids, and metabolites related to MI. This research aims to improve understanding of young adult heart attacks and help tailor future prevention and treatment.
CONDITIONS
Brief Title
UNdeRstAnding Novel Variants in AcutE MyocardiaL Infarction in Young Adults
Who Can Participate
Age: 21Years - 60Years
All Genders
Eligibility Criteria
You may qualify if you...
- Adults over 21 years old
- Age 50 years or younger regardless of cardiovascular risk factors at time of myocardial infarction
- Age 51 to 60 years old with no more than two cardiovascular risk factors excluding diabetes at time of myocardial infarction
- Able to provide informed consent
- Willing and able to comply with study visits and procedures
- Prior type 1 myocardial infarction with angiographic or CT evidence of significant artery narrowing (≥50% in left main or ≥70% in major vessels)
- Self-identified as Chinese, Malay, or Indian
You will not qualify if you...
- Known familial hypercholesterolaemia, vasculitis, end-stage kidney disease, or congenital heart disease
- Prior peripheral artery disease or stroke
- Pregnant females
- Non-Asian patients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Sample Collection
Duration - At enrollment and ongoing assessments as scheduled
Participants provide blood samples for analysis of gene variants and biomarkers associated with myocardial infarction.
1 visit at enrollment; additional visits may occur depending on study assessments
Long-term Monitoring
Duration - Up to 5 years
Participants are followed for up to 5 years to identify novel gene variants and biomarkers related to myocardial infarction.
Periodic visits for assessments during follow-up
Trial Site Locations
Total: 1 location
1
National Heart Centre Singapore
Singapore, Singapore
Actively Recruiting
Loading map...
Research Team
T
Tze Theng Goh
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease Study.
Svati H Shah, Christopher B Granger, Elizabeth R Hauser...
https://pubmed.ncbi.nlm.nih.gov/20826242Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA).
Diane E Bild, Robert Detrano, Do Peterson...
https://pubmed.ncbi.nlm.nih.gov/15769774Genetic variants associated with Lp(a) lipoprotein level and coronary disease.
Robert Clarke, John F Peden, Jemma C Hopewell...
https://pubmed.ncbi.nlm.nih.gov/20032323Genome-wide association identifies a susceptibility locus for coronary artery disease in the Chinese Han population.
Fan Wang, Cheng-Qi Xu, Qing He...
https://pubmed.ncbi.nlm.nih.gov/21378986Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction.
Kouichi Ozaki, Yozo Ohnishi, Aritoshi Iida...
https://pubmed.ncbi.nlm.nih.gov/12426569